Anzeige
Mehr »
Login
Mittwoch, 22.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die Wachstumsgeschichte: Analysten sehen kurzfristige +37 %-Chance bei diesem europäischen Marktführer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
289 Leser
Artikel bewerten:
(1)

MolecuLight Inc.: Latest Clinical Evidence Presented at SAWC 2021 Illustrates the Significant Clinical Utility of the MolecuLight Point-of-Care Imaging Platform

7 Clinical Posters and Presentations Highlight the Breadth of Clinical Benefits
of the MolecuLight Device for Wound Care Applications

TORONTO and LAS VEGAS, Oct. 28, 2021 /PRNewswire/ - MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces the presentation of 7 clinical posters and presentations at the Symposium of Wound Care (SAWC) Fall 2021, held from October 29 - 31, 2021 in Las Vegas, Nevada. SAWC is one of the largest multidisciplinary meetings of wound care professionals.

Latest Clinical Evidence Presented at SAWC 2021 Illustrates the Significant Clinical Utility of the MolecuLight Point-of-Care Imaging Platform

"We are thrilled to have so many customers presenting their impressive clinical findings at this year's SAWC Fall conference", says Anil Amlani, MolecuLight's CEO. "The clinical topics being presented span the wound care continuum, from improved wound assessment and treatment planning, to monitoring of wound cleaning and debridement efficacy, and the resulting improvement in wound healing rates. Presenters will also describe detection and treatment of wound-related cellulitis, and findings from the recently published Delphi consensus-based guidelines for the use of the MolecuLight platform. The outcomes presented in these studies illustrate the significant clinical improvements to wound care provided to clinicians by the MolecuLight i:X".

A submission on MolecuLight by Dr. Charles A. Andersen was one of the top scoring abstracts out of more than 200 submissions. This is the fifth consecutive SAWC meeting at which an abstract on improved patient care achieved through use of the MolecuLighti:X has received this honour.

The 5 clinical posters and 2 presentations featuring the MolecuLight i:X from SAWC Fall 2021 are as follows:

Poster CR-005
12-Week RCT Evaluating Impact of Routine Fluorescence Imaging of Bacteria on DFU Healing Rates
Alisha Oropallo, MD¹, Scott Gawlik DPM¹, Dean Vayser, MD²
¹Northwell Comprehensive Wound Health Center and Hyperbarics, Lake Success NY,
²ILD Research Centre, San Diego, CA
Download poster

Poster CR-006
Cleansing Techniques for Wound Hygiene: Which Are Most Effective?
Alisha Oropallo, MD1, Amit Rao MD1, Jai Joshi1
1Northwell Comprehensive Wound Health Center and Hyperbarics, Lake Success NY
Download poster

Poster LR-025
Detection of bacterial fluorescence from in vivo wound biofilms using a point-of-care
fluorescence imaging device
Andrea J. Lopez1, Laura M. Jones2, Landrye Reynolds1, Rachel C. Diaz1, Isaiah K. George1, William Little1, Derek Fleming3,4, Anna D'souza2, Kendra Rumbaugh3, Allie Clinton Smith1, Monique Y. Rennie2
1Department of Honors Studies, Texas Tech University, Lubbock TX, USA; 2MolecuLight Inc. Toronto, ONCanada; 3Department of Surgery, Texas Tech University Health Sciences Center; 4Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Download poster

Poster CR-020
Are Semi-quantitative Clinical Cultures Inadequate? Comparison to Quantitative Analysis of 1053 Bacterial Isolates from 350 Wounds
Thomas E. Serena1, Phil Bowler2, Gregory Schultz3, Anna D'souza4, Monique Rennie4
1
SerenaGroup Research Foundation, Cambridge MA USA; 2Phil Bowler Consulting, Warrington UK; 3Department of Obstetrics and Gynecology, University of Florida, FL, USA; 4MolecuLight Inc. Toronto
Download poster

Poster PI-003
Guidelines for point-of-care fluorescence imaging for detection of wound bacterial burden based on Delphi consensus
Charles A. Andersen¹, Alisha R. Oropallo², Raymond Abdo³, Jenny Hurlow4, Martha R Kelso5, M. Mark Melin6 and Thomas E. Serena7
1Madigan Army Medical Center, Renton WA; 2.Zucker School of Medicine Hofstra/Northwell, Hempstead, NY; 3St. Louis Foot & Ankle LLC, St. Louis MO; 4Consultant Wound Care Practitioner, Memphis TN; 5Wound Care Plus LLC, Blue Springs MO; 6M Health Fairview, Edina MN; 7SerenaGroup Research Foundation, Cambridge MA Download poster

Oral Presentation & Poster PI-002
Diagnosis and Treatment of the Invasive Extension of Bacteria (Cellulitis) from Chronic Wounds Utilizing Point-of-Care Fluorescence Imaging
Charles Andersen¹, Katherine McLeod¹, Rowena Steffan¹
¹Vascular/Endovascular/Limb Preservation Surgery Service, Madigan Army Medical Center, Joint base Lewis-McChord, WA USA
Download poster

Podium Presentation
Innovation Spotlight: Shining a Light on Bold Ideas in Wound Care
Charles Andersen¹
¹Vascular/Endovascular/Limb Preservation Surgery Service, Madigan Army Medical Center, Joint base Lewis-McChord, WA USA

In additional to the clinical posters and presentations at SAWC (Symposium on Advanced Wound Care) Fall 2021, the recently launched MolecuLightDX will be available for demonstration in the MolecuLight booth #439 in the Exhibit Hall at Caesars Palace in Las Vegas, Nevada.

About MolecuLight Inc.

MolecuLight Inc., a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight's suite of commercially released devices, including the MolecuLight i:X and DX fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

Download for Image:

  • https://moleculight.box.com/s/g0a8y8b9n79vhiwsukaxojicb1t3bgon

contact: Rob Sandler, Chief Marketing Officer, MolecuLight Inc., T. +1.647.362.4684, rsandler@moleculight.com, www.moleculight.com

Photo - https://mma.prnewswire.com/media/1672369/MolecuLight_Latest_Clinical_Evidence_Presented_at_SAWC_2021_Illu.jpg

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.